Is Veozah (Fezolinetant) Safe During Pregnancy?

The Short Answer: Veozah Is Contraindicated in Pregnancy

Fezolinetant must not be taken during pregnancy. The FDA-approved prescribing information for Veozah states explicitly that animal reproduction studies demonstrated fetal harm at exposures near the human therapeutic dose of 45 mg once daily. Because no adequate and well-controlled studies have been conducted in pregnant humans, the drug's safety during human pregnancy cannot be established, and the benefit-risk calculation comes out firmly against use.

This is not a theoretical concern. The NK3 receptor pathway that fezolinetant blocks is active in the placenta and fetal brain, which means interference at doses a woman would actually take could plausibly affect fetal development. The word "contraindicated" in the label is the FDA's strongest safety signal.

If you discovered you are pregnant while taking Veozah, stop the medication and contact your clinician the same day.

Why the Mechanism Matters for Pregnancy Safety

What Fezolinetant Actually Does

Fezolinetant is a selective, non-hormonal NK3 receptor antagonist. Neurokinin B (NKB) is a neuropeptide that acts on NK3 receptors in the hypothalamus to trigger the vasomotor flush reflex responsible for hot flashes. By blocking that receptor, fezolinetant reduces hot flash frequency and severity without manipulating estrogen or progesterone. In the SKYLIGHT 1 and SKYLIGHT 2 trials, 45 mg daily reduced hot flash frequency by approximately 60% at 12 weeks compared with baseline, versus around 45% for placebo, in postmenopausal women.

Why NK3 Receptor Blockade Is a Pregnancy Concern

The NK3 receptor is not restricted to the hypothalamus. NKB and the NK3 receptor are expressed in the placenta, uterine tissue, and the developing fetal nervous system. Research published in reproductive endocrinology literature has established that NKB plays a role in placental vascular regulation and in the hypothalamic-pituitary-gonadal axis maturation of the fetus. Blocking NK3 receptors during organogenesis or fetal brain development is therefore a biologically plausible mechanism for fetal harm, not merely a theoretical extrapolation.

This is why animal studies showing harm are taken seriously, even in the absence of human data. The mechanism predicts the risk.

What the Animal Data Show

The Veozah prescribing label reports that in animal reproduction studies, fezolinetant caused fetal harm when administered at exposures at or near the human equivalent of the 45 mg daily clinical dose. Specific findings included effects on fetal development at doses that did not cause overt maternal toxicity, which is the most concerning pattern because it suggests the fetus is more sensitive than the mother to NK3 blockade. The label does not report a safe dose in animals for pregnancy exposure, meaning no exposure threshold was established below which harm did not occur.

Human Data: What We Know and What We Do Not

No controlled human studies of fezolinetant in pregnancy exist. This is not unusual for a drug approved specifically for postmenopausal women. The clinical trial program, including SKYLIGHT 1, SKYLIGHT 2, SKYLIGHT 4, and the open-label SKYLIGHT 3 extension, enrolled exclusively postmenopausal women with confirmed amenorrhea. Women of reproductive age were excluded. There is no pregnancy registry for Veozah at this time.

The absence of human safety data does not mean "probably safe." When animal data suggest harm and the drug's mechanism provides a biologically plausible pathway to fetal injury, regulatory agencies and clinical guidelines default to contraindication until human safety data exist. ACOG's general framework for drug use in pregnancy reinforces that extrapolation from animal studies to humans must be conservative when a mechanism of harm is biologically credible.

The honest answer is that we simply do not know the human fetal risk of fezolinetant, and the data we do have suggest caution rather than reassurance.

Pregnancy Category and Regulatory Classification

The FDA eliminated the A/B/C/D/X pregnancy letter system in 2015 and replaced it with the Pregnancy and Lactation Labeling Rule (PLLR). Under PLLR, the Veozah label includes a structured Pregnancy subsection with three components:

Risk Summary: States that available animal data demonstrate fetal harm at clinically relevant exposures. No human data. The label advises that Veozah should not be used during pregnancy.

Clinical Considerations: Instructs clinicians to advise patients of reproductive potential to use effective contraception during treatment. The label does not specify a required washout period before conception, but given the drug's half-life of approximately 8 to 11 hours, systemic clearance after stopping is expected within 2 to 3 days. Many clinicians recommend a margin of at least one full menstrual cycle before attempting conception, though this is a conservative clinical preference rather than a label-mandated interval.

Data: Describes the animal reproduction studies that identified fetal harm. See the full prescribing information for the specific animal species, doses, and findings.

Breastfeeding and Fezolinetant

What the Label Says

The Veozah label's Lactation subsection states that there are no data on the presence of fezolinetant in human milk, its effects on the breastfed infant, or its effects on milk production. Because the risk to a breastfed infant cannot be excluded and no human lactation data exist, the label advises that breastfeeding is not recommended during treatment with fezolinetant.

Why This Matters Clinically

Postpartum hot flashes are common and can be severe, particularly in women who choose not to breastfeed or who wean early. Estrogen drops sharply after delivery, and the hypothalamic thermostat becomes transiently dysregulated in a pattern that resembles menopausal vasomotor symptoms. Some women and their clinicians might wonder whether a non-hormonal agent like fezolinetant could help.

The answer right now is no, for two reasons. First, fezolinetant has not been studied in postpartum women, so efficacy in that context is unknown. Second, the drug's safety in breastfed infants is completely unknown. The NK3 receptor is expressed in the developing neonatal brain, and the potential consequences of NK3 blockade through breast milk transfer are not established.

LactMed, the NIH's drug and lactation database, does not yet have a full fezolinetant entry with quantitative milk-transfer data, reflecting the genuine absence of lactation pharmacokinetic studies.

Safe Alternatives for Postpartum Hot Flashes

For women experiencing postpartum vasomotor symptoms, evidence-supported options include:

• Low-dose venlafaxine (37.5 to 75 mg daily): Used off-label for postpartum hot flashes, with data primarily from breast cancer survivorship. Breastfeeding compatibility data exist; LactMed lists venlafaxine as generally compatible with breastfeeding with monitoring for infant sedation.
• Gabapentin (300 mg three times daily): Has some evidence for hot flash reduction; LactMed data suggest low milk transfer, though infant drowsiness monitoring is warranted.
• Non-pharmacologic measures: Cooling strategies, layered clothing, fan use, and avoiding alcohol and spicy food have low-level but consistent evidence for modest symptom reduction.

Talk to your OB or midwife before starting any new medication in the postpartum period, especially while breastfeeding.

Hot Flashes During Pregnancy: A Different Situation

Hot flashes during pregnancy are real and underappreciated. They occur in up to 35% of pregnant women, most commonly in the first and second trimesters, and they are mechanistically distinct from menopausal hot flashes. In pregnancy, the flush is driven by rising progesterone, increased metabolic rate, and increased blood volume rather than by estrogen withdrawal and hypothalamic NKB excess.

Fezolinetant is not indicated for pregnancy-related hot flashes, is contraindicated in pregnancy for the reasons above, and has not been studied in this context. Treating pregnancy hot flashes with a drug that blocks NK3 receptors in the placenta and fetal brain would carry risk without established benefit.

Practical management for hot flashes during pregnancy:

• Identify and avoid triggers (warm environments, spicy food, caffeine).
• Use lightweight, breathable fabrics and keep sleeping environments cool.
• Stay well-hydrated.
• Discuss with your OB if symptoms are interfering significantly with sleep, as some cases may warrant further evaluation (ruling out infection, hyperthyroidism, or anemia as contributing factors).

Who Fezolinetant Is Right For and Who It Is Not

Appropriate Candidates

Fezolinetant is approved for postmenopausal women with moderate-to-severe vasomotor symptoms who want a non-hormonal option. The SKYLIGHT 4 52-week safety trial confirmed that 45 mg once daily maintained efficacy and had an acceptable safety profile in this population over one year. Women who cannot or prefer not to use hormone therapy (for example, those with hormone-receptor-positive breast cancer history, personal preference, or contraindications to estrogen) are the primary population for whom fezolinetant was developed.

Who Should Not Take Fezolinetant

• Pregnant women. Contraindicated.
• Women who are breastfeeding. Not recommended due to unknown risk.
• Women planning pregnancy in the near term who cannot use reliable contraception throughout treatment. The label instructs women of reproductive potential to use effective contraception.
• Women with severe hepatic impairment. Contraindicated due to substantially increased drug exposure.
• Women taking CYP1A2 inhibitors (such as fluvoxamine or ciprofloxacin). Fezolinetant is metabolized by CYP1A2, and inhibitors increase exposure significantly; the combination is contraindicated.
• Women with end-stage renal disease. Use is not recommended.

The Liver Monitoring Requirement

Fezolinetant carries an FDA boxed-adjacent warning about hepatotoxicity. Liver function elevations were seen in the SKYLIGHT 4 trial: approximately 3% of women taking 45 mg daily developed ALT or AST elevations greater than three times the upper limit of normal, compared with 0.7% on placebo. The label requires baseline liver function tests and monitoring at 3 months and 6 months after starting. This monitoring requirement is separate from the pregnancy contraindication but is worth knowing if you are considering Veozah for appropriate indications.

Contraception Requirements for Reproductive-Age Women

The approved indication for fezolinetant is menopausal vasomotor symptoms, so most prescriptions go to women who are already postmenopausal and no longer need contraception. However, women in perimenopause who still have intermittent menstrual cycles are not postmenopausal by definition and may still ovulate unpredictably.

If you are perimenopausal and considering fezolinetant:

1. Confirm with your clinician whether you are truly postmenopausal. The standard clinical definition is 12 consecutive months of amenorrhea without another medical cause.
2. If you are still within the perimenopause transition and there is any possibility of pregnancy, reliable contraception is required throughout fezolinetant treatment.
3. Common contraceptive options compatible with this life stage include progestin-only pills, hormonal IUDs, copper IUDs, and barrier methods. Discuss the best option for your health history with your clinician.

ACOG's guidance on contraception in perimenopause notes that ovulation can occur even with irregular cycles, and pregnancy is possible until 12 months of confirmed amenorrhea.

Evidence Gap: What We Need to Know

Women were historically underrepresented in drug trials, and fezolinetant's clinical program is a reminder that drugs developed for a specific postmenopausal population create substantial knowledge gaps for any woman who might be accidentally exposed during pregnancy or lactation.

The knowledge gaps for fezolinetant are significant:

• No human placental transfer data exist.
• No lactation pharmacokinetic studies have been published.
• The minimum fetal exposure that causes harm in animals was not clearly established.
• There is no pregnancy registry to collect accidental exposure outcomes.

Manufacturers of drugs with contraindications in pregnancy are encouraged by the FDA to establish pregnancy exposure registries. As of the time of publication, Astellas (the manufacturer of Veozah) has not established a public-facing pregnancy registry for fezolinetant. If you took Veozah before knowing you were pregnant, your clinician can report the exposure to FDA MedWatch and to Astellas's pharmacovigilance program to contribute to the accumulating safety signal.

What to Do If You Took Veozah Before Knowing You Were Pregnant

This situation is more likely in perimenopausal women with irregular cycles who may not recognize an early pregnancy. Here is a practical sequence:

1. Stop fezolinetant immediately. Given the 8 to 11-hour half-life, the drug will clear from your system within approximately 2 to 3 days of the last dose.
2. Contact your OB or midwife the same day. Bring the name of the drug, the dose (likely 45 mg), and the dates of exposure.
3. Get a dating ultrasound. Knowing the gestational age at time of exposure helps assess which developmental windows were affected.
4. Report the exposure. Your clinician can submit a MedWatch report to the FDA and notify Astellas. These reports build the pharmacovigilance database that eventually answers the question of human fetal risk.
5. Do not make decisions about the pregnancy based on animal data alone. Animal-to-human extrapolation of teratogenicity is imprecise. Work with a maternal-fetal medicine specialist or a teratology information service such as MotherToBaby (otis.org) to understand your specific risk in context.

Frequently Asked Questions